Stock of the Day

Summit Therapeutics (SMMT)

$19.97

+$0.41 (+2.1%)

Market Cap: $14.65B

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.

The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Recent News

• Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (finance.yahoo.com)
• Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday (msn.com)
• Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday (msn.com)
• Summit Therapeutics: Market Overreaction Creates Opportunity (seekingalpha.com)
• Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? (fool.com)
• Why Summit Therapeutics Inc. (SMMT) Crashed On Friday (msn.com)
• Summit Therapeutics stock dips after clinical trial results (investing.com)
• Summit Therapeutics Shares Slip Following Mixed Results from Lung Cancer Trial (msn.com)
• Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation (msn.com)
• Summit claims late-stage trial win for lung cancer therapy (msn.com)